Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma

Rogers, Jane E; Mizrahi, Jonathan D; Xiao, Lianchun; Mohindroo, Chirayu; Shroff, Rachna T; Wolff, Robert; Varadhachary, Gauri R; Javle, Milind M; Overman, Michael; Fogelman, David R; Raghav, Kanwal P S; Pant, Shubham; McAllister, Florencia

Name:

cam4.3229.pdf

Size:

219.1Kb

Format:

PDF

Description:

Final Published Version

Download

Author

Rogers, Jane E
Mizrahi, Jonathan D
Xiao, Lianchun
Mohindroo, Chirayu
Shroff, Rachna T
Wolff, Robert
Varadhachary, Gauri R
Javle, Milind M
Overman, Michael
Fogelman, David R

Show all

Affiliation

Univ Arizona, Canc Ctr

Issue Date

2020-06-09

Citation

Rogers, J., Mizrahi, J., Xiao, L., Mohindroo, C., Shroff, R., & Wolff, R. et al. (2020). Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Medicine. doi: 10.1002/cam4.3229

Journal

CANCER MEDICINE

Rights

Collection Information

This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.

Abstract

Gemcitabine (GEM) plus nab-paclitaxel (NabP) (GEM 1000 mg/m2 IV over 30 minutes + NabP 125 mg/m2 IV given days 1, 8, and 15 every 28 days) is one of the two standard of care combination therapies for metastatic pancreatic ductal adenocarcinoma (PDAC). Our cancer center has utilized GEM-NabP given every two-weeks due to tolerability and patient convenience. Here, we review the safety and efficacy of this modified regimen.

Note

Open access journal

ISSN

2045-7634

PubMed ID

32519420

DOI

10.1002/cam4.3229

Version

Final published version

Collections

UA Faculty Publications

Copyright © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License.

Except where otherwise noted, this item's license is described as Copyright © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License.